https://biotechmorning.com/news/biotech-556m-double-ipo-hemab-seaport Biotech Morning en 2026-05-09T14:12:41.617Z Biotech's $556M Double IPO Has Wall Street Feeling Something https://biotechmorning.com/news/roche-pathai-billion-dollar-ai-pathology-deal Biotech Morning en 2026-05-09T14:11:59.477Z Roche Just Paid $1 Billion for a Microscope That Thinks https://biotechmorning.com/news/leqembi-subcutaneous-fda-delay Biotech Morning en 2026-05-09T14:11:20.103Z Leqembi's Shortcut to Patients' Homes Just Hit a Roadblock https://biotechmorning.com/news/engene-80-percent-crash-bladder-cancer Biotech Morning en 2026-05-09T14:10:40.568Z The 80% Crash That Redrew Bladder Cancer's Battle Lines https://biotechmorning.com/news/liver-gene-therapy-alzheimers-amyloid Biotech Morning en 2026-05-09T14:09:54.547Z Your Liver Might Be the Secret Weapon Against Alzheimer's https://biotechmorning.com/news/fda-loses-third-commissioner-three-years Biotech Morning en 2026-05-09T14:09:17.007Z The FDA Just Lost Its Third Commissioner in Three Years https://biotechmorning.com/news/roche-pathai-acquisition-billion-dollar-ai-pathology Biotech Morning en 2026-05-08T14:14:05.678Z Roche Just Paid $1 Billion for a Pathologist That Never Sleeps https://biotechmorning.com/news/blackstone-250m-anagram-cystic-fibrosis Biotech Morning en 2026-05-08T14:13:24.639Z The $250M Bet That CF Patients Shouldn't Swallow So Many Pills a Day https://biotechmorning.com/news/ascendis-kills-promising-il2-cancer-drug Biotech Morning en 2026-05-08T14:12:41.230Z Ascendis Had a Promising Cancer Drug. They Killed It Anyway. https://biotechmorning.com/news/odyssey-therapeutics-ipo-comeback Biotech Morning en 2026-05-08T14:12:00.760Z The Biotech IPO That Came Back From the Dead https://biotechmorning.com/news/angelini-acquires-catalyst-pharmaceuticals Biotech Morning en 2026-05-08T14:11:23.482Z Italy's Biggest Bet on American Biotech Just Landed https://biotechmorning.com/news/five-biotech-buyouts-one-week-ma-frenzy Biotech Morning en 2026-05-08T14:10:39.041Z Biotech Buyouts Pile Up: What's Driving the M&A Frenzy?